{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T12:51:29Z","timestamp":1791809489164,"version":"4.3.4"},"reference-count":15,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T00:00:00Z","timestamp":1787616000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jtocrr.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JTO Clinical and Research Reports"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.jtocrr.2026.101072","type":"journal-article","created":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:31:11Z","timestamp":1788222671000},"page":"101072","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Brief Report: Combination Capmatinib and Trametinib in Metastatic MET-Driven NSCLC"],"prefix":"10.1016","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3456-9417","authenticated-orcid":false,"given":"Tyiesha","family":"Brown","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew S.","family":"Lara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward B.","family":"Garon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan W.","family":"Goldman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan W.","family":"Riess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Collin M.","family":"Blakely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtocrr.2026.101072_bib1","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1038\/s41571-025-01051-9","article-title":"Evolving roles of MET as a therapeutic target in NSCLC and beyond","volume":"22","author":"Lee","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jtocrr.2026.101072_bib2","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1016\/S1470-2045(24)00441-8","article-title":"Capmatinib in MET exon 14-mutated non-small-cell lung cancer: final results from the open-label, phase 2 GEOMETRY mono-1 trial","volume":"25","author":"Wolf","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtocrr.2026.101072_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2025.102990","article-title":"Tepotinib in patients with MET exon 14 skipping non-small cell lung cancer","volume":"139","author":"Paik","year":"2025","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.jtocrr.2026.101072_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.currproblcancer.2024.101065","article-title":"Targeting MEK in non-small cell lung cancer","volume":"49","author":"Lara","year":"2024","journal-title":"Curr Probl Cancer"},{"key":"10.1016\/j.jtocrr.2026.101072_bib5","doi-asserted-by":"crossref","first-page":"4498","DOI":"10.1158\/0008-5472.CAN-16-1944","article-title":"MET Exon 14 mutation encodes an actionable therapeutic target in lung adenocarcinoma","volume":"77","author":"Lu","year":"2017","journal-title":"Cancer Res"},{"key":"10.1016\/j.jtocrr.2026.101072_bib6","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1158\/2159-8290.CD-15-0285","article-title":"Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors","volume":"5","author":"Frampton","year":"2015","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jtocrr.2026.101072_bib7","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1158\/2159-8290.CD-14-1467","article-title":"Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping","volume":"5","author":"Paik","year":"2015","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jtocrr.2026.101072_bib8","doi-asserted-by":"crossref","first-page":"e101","DOI":"10.1016\/j.cllc.2015.01.009","article-title":"Response to crizotinib in a patient with lung adenocarcinoma harboring a MET splice site mutation","volume":"16","author":"Jenkins","year":"2015","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.jtocrr.2026.101072_bib9","doi-asserted-by":"crossref","first-page":"e33","DOI":"10.1097\/JTO.0000000000000491","article-title":"MET-mutated NSCLC with major response to crizotinib","volume":"10","author":"Mendenhall","year":"2015","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtocrr.2026.101072_bib10","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1097\/JTO.0000000000000478","article-title":"MET mutation associated with responsiveness to crizotinib","volume":"10","author":"Waqar","year":"2015","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtocrr.2026.101072_bib11","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1200\/JCO.2015.62.0674","article-title":"Next-generation sequencing of pulmonary sarcomatoid carcinoma reveals high frequency of actionable MET gene mutations","volume":"34","author":"Liu","year":"2016","journal-title":"J Clin Oncol"},{"issue":"15_suppl","key":"10.1016\/j.jtocrr.2026.101072_bib12","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.34.15_suppl.9067","article-title":"Phase (Ph) I study of the safety and efficacy of the cMET inhibitor capmatinib (INC280) in patients (pts) with advanced cMET+ non-small cell lung cancer (NSCLC)","volume":"34","author":"Schuler","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtocrr.2026.101072_bib13","doi-asserted-by":"crossref","first-page":"S438","DOI":"10.1016\/j.jtho.2016.11.512","article-title":"MA16.09 Antitumor activity and safety of crizotinib in patients with MET exon 14-altered advanced non-small cell lung cancer","volume":"12","author":"Drilon","year":"2017","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtocrr.2026.101072_bib14","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1158\/1078-0432.CCR-19-1667","article-title":"Co-occurring alterations in the RAS-MAPK pathway limit response to MET inhibitor treatment in MET Exon 14 skipping mutation-positive lung cancer","volume":"26","author":"Rotow","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtocrr.2026.101072_bib15","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1186\/s12885-025-14068-1","article-title":"A phase Ia\/b study of MEK1\/2 inhibitor binimetinib with MET inhibitor crizotinib in patients with RAS mutant advanced colorectal cancer (MErCuRIC)","volume":"25","author":"Aroldi","year":"2025","journal-title":"BMC Cancer"}],"container-title":["JTO Clinical and Research Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666364326001232?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666364326001232?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T12:42:33Z","timestamp":1791808953000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666364326001232"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":15,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S2666364326001232"],"URL":"https:\/\/doi.org\/10.1016\/j.jtocrr.2026.101072","relation":{},"ISSN":["2666-3643"],"issn-type":[{"value":"2666-3643","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Brief Report: Combination Capmatinib and Trametinib in Metastatic MET-Driven NSCLC","name":"articletitle","label":"Article Title"},{"value":"JTO Clinical and Research Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtocrr.2026.101072","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of the International Association for the Study of Lung Cancer.","name":"copyright","label":"Copyright"}],"article-number":"101072"}}